Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865

Piper Sandler analyst Biren Amin has maintained an Overweight rating on Regeneron Pharmaceuticals (NASDAQ: REGN) and raised the price target from $854 to $865. This adjustment reflects a positive outlook on the company's performance.